A U.S. appeals court has reinstated more than 500 lawsuits against drugmaker Merck & Co. because of its osteoporosis drug Fosamax, which plaintiffs allege increases risk of thigh bone fractures, ...

Shares of Merck & Co. Inc. MRK shed 1.31% to $115.63 Monday, on what proved to be an all-around great trading session for the ...

The decision, which the U.S. Court of Appeals for the Third Circuit said was a close call, hinged on whether an informal ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Sutro Biopharma specializes in ADCs for oncology and shows promise with STRO-002 for ovarian cancer and collaborations with ...

More than 500 lawsuits, which a U.S. appeals court revived on Friday, allege Merck & Co. failed to warn patients that its osteoporosis drug Fosamax raised the risk of thigh bone fractures. Separately, ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), ...

Watch CEO of Immuta, Matthew Carroll's fireside chat with Alessandra De Almeida, Executive Director of Data Management & Governance at Merck, exploring Merck's transformative data management journey.

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Financial writer bullish on the Health Care Select Sector SPDR ETF (XLV) for its valuation, technical setup, and diversified ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...